» Articles » PMID: 35694767

IC50: an Unsuitable Measure for Large-sized Prostate Cancer Spheroids in Drug Sensitivity Evaluation

Overview
Specialty General Medicine
Date 2022 Jun 13
PMID 35694767
Authors
Affiliations
Soon will be listed here.
Abstract

Preclinical models of tumors have the potential to become valuable tools for commercial drug research and development, and 3D culture systems are gaining traction in this area, particularly in prostate cancer (PCa) research. However, nearly all 3D drug design and screening assessments are based on 2D experiments, suggesting limitations of 3D drug testing. To simulate the natural response of human cells to the drug, we detected the half-maximal inhibitory concentration (IC50) changes of 2D/3D LNCaP cells in the drug docetaxel, as well as the sensitivity of different morphologies of 2D/3D LNCaP to docetaxel treatment. In contrast to 2D LNCaP cells, the evaluation of LNCaP spheroids' susceptibility to treatment was more complicated; the fitness of IC50 curves of 2D and 3D tumor cell preclinical models differs significantly. IC50 curves were unsuitable for large-sized LNCaP spheroids. More evaluation indexes (such as max inhibition) and experiments (such as spheroids formation) should be explored and performed to evaluate the susceptibility systematically.

Citing Articles

Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy.

Sanchez-Diez M, Romero-Jimenez P, Alegria-Aravena N, Gavira-ONeill C, Vicente-Garcia E, Quiroz-Troncoso J Pharmaceutics. 2025; 17(2).

PMID: 40006615 PMC: 11859577. DOI: 10.3390/pharmaceutics17020247.


Exploring the significance and potential mechanisms of hippo pathway-associated genes in prognosis of glioma patients.

Liu X, Fan H, Chen Z, Liu C Discov Oncol. 2024; 15(1):536.

PMID: 39382606 PMC: 11464986. DOI: 10.1007/s12672-024-01391-5.


Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.

Petric T, Sabol M Int J Mol Sci. 2023; 24(6).

PMID: 36982368 PMC: 10049142. DOI: 10.3390/ijms24065293.


Corrigendum: IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.

Biomol Biomed. 2023; 23(3):545.

PMID: 36724044 PMC: 10171451. DOI: 10.17305/bb.2022.8739.


Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines.

Karner C, Anders I, Vejzovic D, Szkandera J, Scheipl S, Deutsch A J Transl Med. 2023; 21(1):54.

PMID: 36710341 PMC: 9884415. DOI: 10.1186/s12967-022-03843-4.


References
1.
Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View

2.
Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M . Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep. 2015; 33(4):1837-43. DOI: 10.3892/or.2015.3767. View

3.
Atefi E, Lemmo S, Fyffe D, Luker G, Tavana H . High Throughput, Polymeric Aqueous Two-Phase Printing of Tumor Spheroids. Adv Funct Mater. 2014; 24(41):6509-6515. PMC: 4233147. DOI: 10.1002/adfm.201401302. View

4.
Elbadawy M, Abugomaa A, Yamawaki H, Usui T, Sasaki K . Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research. Cancers (Basel). 2020; 12(4). PMC: 7226333. DOI: 10.3390/cancers12040777. View

5.
Arrowsmith J . Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov. 2011; 10(2):87. DOI: 10.1038/nrd3375. View